4//SEC Filing
Umstead John W. V 4
Accession 0001562180-24-004063
CIK 0001560241other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 4:11 PM ET
Size
9.8 KB
Accession
0001562180-24-004063
Insider Transaction Report
Form 4
Umstead John V.
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-05-13$4.79/sh−8,151$39,034→ 153,245 total
Footnotes (3)
- [F1]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F2]The price represents the weighted average price with a low of $4.62 and a high of $4.98. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Represents (i) 18,770 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 37,500 RSUs from award granted on March 15, 2023; (vi) 17,500 RSUs from award granted on May 10, 2023; (vii) 37,300 RSU's granted on January 3, 2024; and (viii) 37,500 RSUs granted on March 20, 2024.
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001967910
Filing Metadata
- Form type
- 4
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 4:11 PM ET
- Size
- 9.8 KB